Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IN8Z
|
|||
| Former ID |
DNCL003814
|
|||
| Drug Name |
LY2928057
|
|||
| Indication | Anaemia [ICD-11: 3A90; ICD-10: D64.8] | Phase 2 | [1] | |
| Company |
Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Solute carrier family 40 member 1 (SLC40A1) | Target Info | Modulator | [2] |
| KEGG Pathway | Mineral absorption | |||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | Iron uptake and transport | |||
| WikiPathways | Iron uptake and transport | |||
| Iron metabolism in placenta | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017 Jun;16(6):400-423. | |||
| REF 2 | Targeting the Hepcidin-Ferroportin Axis to Develop New Treatment Strategies for Anemia of Chronic Disease and Anemia of Inflammation. Am J Hematol. 2012 April; 87(4): 392-400. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.